TB vaccine research and development is complex and costly. No one organization or institution can do it alone. Aeras works in partnership with individuals, research organizations, academic institutions, funders, policymakers, and others to advance TB vaccine science. Due to limited resources and the complex biology of TB, it is crucial for scientists in this field to share knowledge and work together.
Some of Aeras’ partners include:
- The European and Developing Countries Clinical Trials Partnership (EDCTP) provides crucial funding for TB vaccine trials and enhances clinical trial site capacity.
- The South African Tuberculosis Vaccine Initiative (SATVI) partners with Aeras on clinical trials of potential TB vaccine candidates.
- The TuBerculosis Vaccine Initiative (TBVI), which is based in Europe, partners with Aeras on basic research to discover and advance innovative TB vaccine science and candidates.
- The China National Biotech Group (CNBG), the largest biotech in China, works jointly with Aeras to develop TB vaccines.